Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
University of Washington
mi
from
Seattle, WA
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Updated: 1/1/1970
University of Washington
mi
from
Seattle, WA
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Spokane Cardiology
mi
from
Spokane, WA
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Updated: 1/1/1970
Spokane Cardiology
mi
from
Spokane, WA
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Inland Cardiology Associates
mi
from
Spokane, WA
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Updated: 1/1/1970
Inland Cardiology Associates
mi
from
Spokane, WA
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Wisconsin Heart, SC
mi
from
Madison, WI
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Status: Archived
Updated: 1/1/1970
Wisconsin Heart, SC
mi
from
Madison, WI
Family Cardiac Caregiver Investigation to Evaluate Outcomes
Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Family Cardiac Caregiver Investigation to Evaluate Outcomes
Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Dose-dependent Effects of Second-hand Smoke on Vascular Function
Dose-dependent Biological Mechanisms of Second-hand Smoke on Endothelial Function and Oxidative Stress
Status: Archived
UCSF Psoriasis and Skin Treatment Center
mi
from
San Francisco, CA
Dose-dependent Effects of Second-hand Smoke on Vascular Function
Dose-dependent Biological Mechanisms of Second-hand Smoke on Endothelial Function and Oxidative Stress
Status: Archived
Updated: 1/1/1970
UCSF Psoriasis and Skin Treatment Center
mi
from
San Francisco, CA
The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk
The Effect of Vitamin D Repletion on Small LDL Particle Number in Subjects at Elevated Cardiovascular Risk
Status: Archived
The Rockefeller University Hospital
mi
from
New York, NY
The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk
The Effect of Vitamin D Repletion on Small LDL Particle Number in Subjects at Elevated Cardiovascular Risk
Status: Archived
Updated: 1/1/1970
The Rockefeller University Hospital
mi
from
New York, NY
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D
Status: Archived
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D
Status: Archived
Updated: 1/1/1970
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Doxycycline Outcomes in Lupus Erythematosus: (DOLE)
Doxycycline Outcomes in Lupus Erythematosus: (DOLE)
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Doxycycline Outcomes in Lupus Erythematosus: (DOLE)
Doxycycline Outcomes in Lupus Erythematosus: (DOLE)
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
The Ex-Lex Trial: A Randomized Trial Combining Regadenoson With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
Status: Archived
Center for Fertility and Women's Health
mi
from
New Britain, CT
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
The Ex-Lex Trial: A Randomized Trial Combining Regadenoson With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
Status: Archived
Updated: 1/1/1970
Center for Fertility and Women's Health
mi
from
New Britain, CT
Prevent Return of Stroke Study
Preventing Recurrence of All Inner-city Strokes Through Education
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Prevent Return of Stroke Study
Preventing Recurrence of All Inner-city Strokes Through Education
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Resistant Starch Insulin Sensitivity Trial
Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance
Status: Archived
Cholesterol Research Center
mi
from
Berkeley, CA
Resistant Starch Insulin Sensitivity Trial
Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance
Status: Archived
Updated: 1/1/1970
Cholesterol Research Center
mi
from
Berkeley, CA
Resistant Starch Insulin Sensitivity Trial
Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Resistant Starch Insulin Sensitivity Trial
Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
A Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations
Prospective Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations
Status: Archived
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
A Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations
Prospective Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations
Status: Archived
Updated: 1/1/1970
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
ROS Signaling in Endothelial Function
ROS Signaling in Endothelial Function
Status: Archived
Boston Med Center
mi
from
Boston, MA
ROS Signaling in Endothelial Function
ROS Signaling in Endothelial Function
Status: Archived
Updated: 1/1/1970
Boston Med Center
mi
from
Boston, MA
Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells
Evaluation of the Relationships of Time and Dose of Eicosapentaenoic Acid and Stearidonic Acid to the Changes in Eicosapentaenoic Acid Levels in Red Blood Cells
Status: Archived
Provident Clinical Research
mi
from
Bloomington, IN
Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells
Evaluation of the Relationships of Time and Dose of Eicosapentaenoic Acid and Stearidonic Acid to the Changes in Eicosapentaenoic Acid Levels in Red Blood Cells
Status: Archived
Updated: 1/1/1970
Provident Clinical Research
mi
from
Bloomington, IN
Comparison of Digital Electronic Stethoscope to Computed Tomography (CT) Angiography in Detection of Coronary Artery Disease
Validation of the Cardiosond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography
Status: Archived
North Shore University Hospital
mi
from
Manhasset, NY
Comparison of Digital Electronic Stethoscope to Computed Tomography (CT) Angiography in Detection of Coronary Artery Disease
Validation of the Cardiosond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography
Status: Archived
Updated: 1/1/1970
North Shore University Hospital
mi
from
Manhasset, NY
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
Status: Archived
Oregon Stroke Center, OHSU
mi
from
Portland, OR
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
Status: Archived
Updated: 1/1/1970
Oregon Stroke Center, OHSU
mi
from
Portland, OR
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
Status: Archived
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
SOLITAIREâ„¢ FR With the Intention For Thrombectomy (SWIFT) Study
Status: Archived
Updated: 1/1/1970
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification
CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification
Status: Archived
Walter Reed Army Medical Center
mi
from
Washington,
CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification
CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification
Status: Archived
Updated: 1/1/1970
Walter Reed Army Medical Center
mi
from
Washington,
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Jules Stein Eye Institute, University of California, Los Angeles
mi
from
Los Angeles, CA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Jules Stein Eye Institute, University of California, Los Angeles
mi
from
Los Angeles, CA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado
mi
from
Aurora, CO
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado
mi
from
Aurora, CO
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Bascom Palmer Eye Institute
mi
from
Miami, FL
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Bascom Palmer Eye Institute
mi
from
Miami, FL
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Kansas University Medical Center
mi
from
Kansas City, KA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Kansas University Medical Center
mi
from
Kansas City, KA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
University of Kentucky Hospital
mi
from
Lexington, KY
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
University of Kentucky Hospital
mi
from
Lexington, KY
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Mason Eye Institute, University of Missouri
mi
from
Columbia, MO
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Mason Eye Institute, University of Missouri
mi
from
Columbia, MO
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Glaucoma Associates of New York/New York Eye and Ear Infirmary
mi
from
New York, NY
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Glaucoma Associates of New York/New York Eye and Ear Infirmary
mi
from
New York, NY
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
The Flaum Eye Institute-University of Rochester
mi
from
Rochester, NY
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
The Flaum Eye Institute-University of Rochester
mi
from
Rochester, NY
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Western Carolina Retinal Associates
mi
from
Asheville, NC
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Western Carolina Retinal Associates
mi
from
Asheville, NC
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Charlotte Eye Ear Nose and Throat Assoc, PA
mi
from
Charlotte, NC
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Charlotte Eye Ear Nose and Throat Assoc, PA
mi
from
Charlotte, NC
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Duke University Hospital
mi
from
Durham, NC
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Duke University Hospital
mi
from
Durham, NC
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Cole Eye Institute - Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Cole Eye Institute - Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Allegheny Ophthalmic and Orbital Associates
mi
from
Pittsburgh, PA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
Allegheny Ophthalmic and Orbital Associates
mi
from
Pittsburgh, PA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
John Moran Eye Center
mi
from
Salt Lake City, UT
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
John Moran Eye Center
mi
from
Salt Lake City, UT
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
VCU Medical Center
mi
from
Richmond, VA
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status: Archived
Updated: 1/1/1970
VCU Medical Center
mi
from
Richmond, VA
Trial of a Secondary Stroke Prevention Program
Development of a Stroke Prevention Program for an Underserved Minority Community
Status: Archived
Veterans Affairs Medical Center - Lakeside Chicago
mi
from
Chicago, IL
Trial of a Secondary Stroke Prevention Program
Development of a Stroke Prevention Program for an Underserved Minority Community
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - Lakeside Chicago
mi
from
Chicago, IL
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Partners HealthCare
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Partners HealthCare
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
VA Boston Health Care System
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
VA Boston Health Care System
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
Status: Archived
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA